Description
Derazantinib is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. It binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells.
Derazantinib is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. It binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells.
B2222 | Derazantinib (ARQ087) DataSheet
Alternate Name/Synonyms: (6R)-6-(2-fluorophenyl)-N-(3-{2-[(2-methoxyethyl)amino]ethyl}phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine; ARQ-087
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 1234356-69-4
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₉H₂₉FN₄O
Molecular Weight: 468.58
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A fibroblast growth factor receptor (FGFR) inhibitor
MDL Number: N/A
PubChem CID: 46834118
SMILES: COCCNCCC1=CC(=CC=C1)NC2=NC=C3CC(C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
InChi: InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
InChi Key: KPJDVVCDVBFRMU-AREMUKBSSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |